Determination of features indicating progression in atypical squamous cells with undetermined significance (original) (raw)

Abstract

BACKGROUND. The Bethesda System of cervical cytologic findings introduced the term ASCUS (atypical squamous cells of undetermined significance) to cover the broad zone separating normal cytomorphology from definitive squamous intraepithelial lesions (SILs ). The management of patients with ASCUS is particularly problematic as approximately 10% of ASCUS patients develop SIL and 1 per 1000 develop cervical carcinoma.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (28)

  1. The 1988 Bethesda System for reporting cervical/vaginal cytologic diagnoses. Acta Cytol. 1989;33:567-572.
  2. The revised Bethesda System for reporting cervical/vaginal cytologic diagnoses: report of the 1991 Bethesda workshop. Acta Cytol. 1992;36:273-276.
  3. Solomon D, Frable WJ, Vooijs GP, et al. ASCUS and AGUS criteria. International Academy of Cytology Task Force sum- mary. Acta Cytol. 1998;42:16 -24.
  4. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cer- vical cytology The 1992 National Cancer Institute Workshop. JAMA. 1994;271:1866 -1869.
  5. Smith-Mccune K, Mancuso V, Contant T, Jackson R. Man- agement of women with atypical tests of undetermined significance by board-certified gynecologists: discrepancies with published guidelines. Am J Obstet Gynecol. 2001;185: 551-556.
  6. Cenci M, Vecchione A. Atypical squamous and glandular cells of undetermined significance (ASCUS and AGUS) of the uterine cervix. Anticancer Res. 2000;20(5c):3701- 3707.
  7. Manos MM, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA. 1999;281: 1605-1610.
  8. Sherman ME, Solomon D, Schiffman M. Qualification of ASCUS: a comparison of equivocal LSIL and equivocal HSIL cervical cytology in the ASCUS LSIL triage study. Am J Clin Pathol. 2001;116:386 -394.
  9. Joste NE, Rushing L, Granados R, et al. Bethesda classifica- tion of cervicovaginal smears: reproducibility and viral cor- relates. Hum Pathol. 1996;27:581-585.
  10. Rihet S, Lorenzato M, Clavel C. Oncogenic human papillo- maviruses and ploidy in cervical lesions. J Clin Pathol. 1996; 49:892-896.
  11. Bo ¨cking A, Hilgarth M, Auffermann W, Hack-Werdier C, Fischer-Becker D, von Kalkreuth D. DNA cytometric diag- nosis of prospective malignancy in borderline lesions of the uterine cervix. Acta Cytol. 1986;39:608 -615.
  12. Steinbeck RG. Proliferation and DNA aneuploidy in mild dysplasia imply early steps of cervical carcinogenesis. Acta Oncol. 1997;36:3-12.
  13. Anton M, Nenutil R, Rejthar A, Kopecny J, Ptackova B, Zaloudik J. DNA flow cytometry: a predictor of a high-risk group in cervical cancer. Cancer Detect Prev. 1997;23:242- 246.
  14. Bollmann R, Bollmann M, Henson DE, Bodo M. DNA cy- tometry confirms the utility of the Bethesda System for the classification of Papanicolaou smears. Cancer (Cancer Cyto- pathol). 2001;93:222-228.
  15. Hanselaar AG, Bocking A, Gundlach H, et al. Summary state- ment on quantitative cytochemistry (DNA and molecular biology): task force 8. Acta Cytol. 2001;45:499 -501.
  16. Park IA, Lee SN, Chae SW, Park KH, Kim JW, Lee HP. Com- paring the accuracy of ThinPrep Pap test and conventional Papanicolaou smears on the basis of histological diagnosis: a clinical study of women with cervical abnormalities. Acta Cytol. 2001;45:525-531.
  17. Feoli-Fonseca JC, Oligny LL, Filion M, et al. A two tier polymerase chain reaction direct sequencing method for detecting and typing human papillomaviruses in patholog- ical specimens. Diagn Mol Pathol. 1998;7:317-323.
  18. Jacobs MV, Snijders PJ, van den Brule JC, Helmerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5ϩ/GP6ϩ- mediated PCR-enzyme immunoassay method for rapid de- tection of 14 high risk and 6 low risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol. 1997;35: 791-795.
  19. Bauer HM, Greer CE, Manos MM. Determination of genital HPV infection using consensus PCR. In: Herrington CS, Mc- Gee JO. Diagnostic molecular pathology: a practical ap- proach. Oxford: Oxford University Press, 1992:131-152.
  20. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst. 1995;87:779 -780.
  21. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical can- cer worldwide. J Pathol. 1999;189:12-19.
  22. zur Hausen H. Cervical carcinoma and human papilloma- virus: on the road to preventing a major human cancer. J Natl Cancer Inst. 2001;93:252-253.
  23. Crum CP. Contemporary theories of cervical carcinogenesis: the virus, the host and the stem cell. Mod Pathol. 2000;13: 243-251.
  24. Matsukura T, Sugase M. Relationship between 80 human papillomavirus genotypes and different grades of cervical intraepithelial neoplasia: association and causality Virology. 2001;283:139 -147.
  25. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol. 1992;79:328 -337.
  26. Bollmann R, Torka R, Schmitz J, Bollmann M, Me ´hes G. De- termination of ploidy and steroid receptor status in breast cancer by laser scanning cytometry. Cytometry (Clin Cytom- etry). 2002;50:210 -215.
  27. Winkler B, Crum CP, Fujii T, et al. Koilocytic lesions of the cervix: the relationship of mitotic abnormalities to the pres- ence of papillomavirus antigens and nuclear DNA content. Cancer. 1984;53:1081-1087.
  28. Chatelain R, Schunck T, Schindler EM, Schindler AE, Bo ¨ck- ing A. Diagnosis of prospective malignancy in koilocytic dysplasias of the cervix with DNA cytometry. J Reprod Med. 1989;34:505-510.